Press Release

LivaNova Announces One-Millionth Patient Treated with Advanced XTRA Autotransfusion System

LONDON--(BUSINESS WIRE)--Oct. 2, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced its innovative autotransfusion system (ATS), XTRA®, has treated its one-millionth patient at Houston Methodist Hospital in Houston.

This Smart News Release features multimedia. View the full release here:

LivaNova commemorates the one-millionth patient treated with its XTRA® autotransfusion system with t ...

LivaNova commemorates the one-millionth patient treated with its XTRA® autotransfusion system with the multidisciplinary blood management team at Houston Methodist Hospital. (Photo: Business Wire)

Used during and after surgical operations, XTRA is the innovative, intuitive and powerful ATS system, a cost-effective solution that aims to improve patient outcome by reducing the exposure to allogeneic transfusions and the associated risks.

“With the decreasing worldwide availability of allogeneic blood and the risks associated with its transfusion, there has been a shift in the healthcare community to optimize the use of autotransfusion,” said Kimberly Roy, a certified perioperative blood management technologist with Houston Methodist Hospital, who treated the one-millionth patient. “The implementation of a blood management strategy, especially with the use of autotransfusion systems, has reduced the level of risks associated with transfusion.”

The XTRA system provides the safe and effective collection, processing and reinfusion of patient blood during surgery. Designed as an intuitive and information-rich system, XTRA features advanced patient data management capabilities and an accessible graphic touchscreen interface. The system can be used during and after a range of surgical procedures, including cardiac, high-bleeding or emergency operations, orthopedic and pre-operative sequestration.

“For more than three decades, LivaNova has developed and delivered state-of-the-art autotransfusion solutions for patients,” said Brian Duncan, M.D., LivaNova’s Vice President of Medical Affairs for the Cardiac Surgery franchise. “We are proud to reach this milestone for the innovative XTRA system. We look forward to continuing to address vital needs of healthcare providers and hospitals for blood management strategies during surgery.”

To learn more about XTRA and LivaNova’s portfolio of autotransfusion solutions, please visit

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than 100 countries worldwide, the company employs more than 4,500 employees. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively.

For more information, please visit

Safe Harbor Statement

Any forward-looking statements are subject to risks and uncertainties such as those described in LivaNova’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Source: LivaNova PLC

LivaNova PLC Investor Relations and Media
Karen King, +1 (281) 228-7262
Vice President, Investor Relations & Corporate Communications
Deanna Wilke, +1 (281) 727-2764
Corporate External Communications Manager